The failure of this phase III study might be due to intrinsic factors such as the upregulation of drug efflux channels which might impact the intracellular concentration of irinotecan [194], or the decreases of CD44 expression which would render the tumor cells largely less responsive to CD44‐targeted treatment [195]. Here, CD44 is linked to neoplasm.